EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor (Q39698180)

14 September 2017

EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor (English)

1 reference

14 September 2017

1 reference

1 reference

L Su

1

1 reference

14 September 2017

H Cheng

2

1 reference

14 September 2017

A V Sampaio

3

1 reference

14 September 2017

T O Nielsen

4

1 reference

14 September 2017

T M Underhill

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

31 May 2010

1 reference

14 September 2017

1 reference

14 September 2017

29

1 reference

14 September 2017

30

1 reference

14 September 2017

4352-4361

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2010.204

14 September 2017

0 references

cites work

Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Anticancer activities of histone deacetylase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Early growth response-1-dependent apoptosis is mediated by p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Site-specific acetylation of p53 directs selective transcription complex assembly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

HDAC inhibitor-based therapies and haematological malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

PTEN regulation by Akt-EGR1-ARF-PTEN axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.204

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.204

1 reference

Dimensions Publication ID

14 September 2017

0 references

1 reference